1-9 of 9
Anne-Marie C. Dingemans
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies

Alessio Cortellini, Anne-Marie C. Dingemans, Oscar Arrieta, Javier Baena, Matteo Brighenti, Enriqueta Felip, Marina Chiara Garassino, Pilar Garrido, Carlo Genova, Federica Grosso, Leora Horn, Li-Ching Huang, Jan Van Meerbeeck, Solange Peters, Ernest Nadal, Jacobo Rogado, Yu Shyr, Marcello Tiseo, Valter Torri, Annalisa Trama, Heather Wakelee, Jennifer G Whisenant, Giuseppe Viscardi, Fabrice Barlesi, Sanjay Popat
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (18_Supplement): S12-03.
https://doi.org/10.1158/1557-3265.COVID-19-S12-03
Published: 15 September 2020
View article titled, Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies
Journal Articles

Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients

Pauline L. de Goeje, Myrthe Poncin, Koen Bezemer, Margaretha E.H. Kaijen-Lambers, Harry J.M. Groen, Egbert F. Smit, Anne-Marie C. Dingemans, André Kunert, Rudi W. Hendriks, Joachim G.J.V. Aerts
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2219–2227.
https://doi.org/10.1158/1078-0432.CCR-18-2243
Published: 01 April 2019
View article titled, Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients
Open the PDF for Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non–small Cell Lung Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

Jules L. Derks, Noémie Leblay, Erik Thunnissen, Robert Jan van Suylen, Michael den Bakker, Harry J.M. Groen, Egbert F. Smit, Ronald Damhuis, Esther C. van den Broek, Amélie Charbrier, Matthieu Foll, James D. McKay, Lynnette Fernandez-Cuesta, Ernst-Jan M. Speel, Anne-Marie C. Dingemans
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (1): 33–42.
https://doi.org/10.1158/1078-0432.CCR-17-1921
Published: 02 January 2018
View article titled, Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome
Open the PDF for Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome in another window
Includes: Supplementary data
Journal Articles

CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids

Dorian R.A. Swarts, Mieke E.R. Henfling, Leander Van Neste, Robert-Jan van Suylen, Anne-Marie C. Dingemans, Winand N.M. Dinjens, Annick Haesevoets, Martina Rudelius, Erik Thunnissen, Marco Volante, Wim Van Criekinge, Manon van Engeland, Frans C.S. Ramaekers, Ernst-Jan M. Speel
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2197–2207.
https://doi.org/10.1158/1078-0432.CCR-12-3078
Published: 15 April 2013
View article titled, CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids
Open the PDF for CD44 and OTP Are Strong Prognostic Markers for Pulmonary Carcinoids in another window
Includes: Supplementary data
Journal Articles

A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a KRAS Mutation

Anne-Marie C. Dingemans, Wouter W. Mellema, Harry J.M. Groen, Atie van Wijk, Sjaak A. Burgers, Peter W.A. Kunst, Erik Thunnissen, Danielle A.M. Heideman, Egbert F. Smit
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (3): 743–751.
https://doi.org/10.1158/1078-0432.CCR-12-1779
Published: 31 January 2013
View article titled, A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a <em>KRAS</em> Mutation
Open the PDF for A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non–Small Cell Lung Cancer with a <em>KRAS</em> Mutation in another window
Journal Articles

Abstract A31: Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy

Wouter W. Mellema, Anne-Marie C. Dingemans, Egbert F. Smit, Jules Derks, Daniëlle A.M. Heideman, Robertjan van Suylen, Frederik B. Thunnissen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): A31.
https://doi.org/10.1158/1078-0432.12AACRIASLC-A31
Published: 01 February 2012
View article titled, Abstract A31: Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy
Open the PDF for Abstract A31: Predictive and prognostic value of KRAS mutations in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy in another window
Journal Articles

Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation

Wouter W. Mellema, Anne-Marie C. Dingemans, Harry J.M. Groen, Atie van Wijk, Sjaak Burgers, Peter W.A. Kunst, Frederik B. Thunnissen, Daniëlle A.M. Heideman, Egbert F. Smit
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): PR5.
https://doi.org/10.1158/1078-0432.12AACRIASLC-PR5
Published: 01 February 2012
View article titled, Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation
Open the PDF for Abstract PR5: A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-Ras mutation in another window
Journal Articles

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer

Joline S.W. Lind, Anne-Marie C. Dingemans, Harry J.M. Groen, Frederik B. Thunnissen, Otto Bekers, Daniëlle A.M. Heideman, Richard J. Honeywell, Elisa Giovannetti, Godefridus J. Peters, Pieter E. Postmus, Robert Jan van Suylen, Egbert F. Smit
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 3078–3087.
https://doi.org/10.1158/1078-0432.CCR-09-3033
Published: 31 May 2010
View article titled, A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
Open the PDF for A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Expression of DNA Topoisomerase IIα and Topoisomerase IIβ Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer

Anne-Marie C. Dingemans, M. Adhiambo Witlox, Roland A. L. M. Stallaert, Paul van der Valk, Pieter E. Postmus, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (8): 2048–2058.
Published: 01 August 1999
View article titled, Expression of DNA Topoisomerase IIα and Topoisomerase IIβ Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer
Open the PDF for Expression of DNA Topoisomerase IIα and Topoisomerase IIβ Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer in another window